

**North Central London**

**Joint Formulary Committee**

|  |
| --- |
| **Guideline name** |

**Disclaimer**

This guideline is registered at North Central London (NCL) Joint Formulary Committee (JFC) and is intended solely for use by healthcare professionals to aid the treatment of patients within NCL. However, clinical guidelines are for guidance only, their interpretation and application remain the responsibility of the individual clinician. If in doubt, contact a senior colleague or expert. Clinicians are advised to refer to the manufacturer’s current prescribing information before treating individual patients.

The authors and NCL JFC accept no liability for use of this information from this beyond its intended use.

While we have tried to compile accurate information in this guideline, and to keep it updated in a timely manner, we cannot guarantee that it is fully complete and correct at all times. If you identify information within this guideline that is inaccurate, please report this to the admin.ncl-mon@nhs.net. If a patient is harmed as a consequence of following this guideline, please complete a local incident report and inform admin.ncl-mon@nhs.net.

This guideline should not be to used or reproduced for commercial or marketing purposes.

NCL JFC is funded by and provides advice to Acute Trusts and Clinical Commissioning Groups in NCL.

**Document control**

|  |  |  |
| --- | --- | --- |
| Date | Version | Amendments |
|  |  |  |

**Document management**

|  |
| --- |
| **Document draft tracking; table will be removed before publication** |
| **Issue** | **Author(s)** | **Owner** | **Date** | **Circulation** | **Comments** |
| Draft 1 |  |  |  |  |  |
| Draft 2 |  |  |  |  |  |
| Draft 3 |  |  |  |  |  |
| Draft 4 |  |  |  |  |  |
| Draft 5 |  |  |  |  |  |

|  |  |
| --- | --- |
| Groups / Individuals who have overseen the development of this guidance: |  |
| Groups which were consulted and have given approval: |  |
| File name: | Document2 |
| Version number: |  |
| Available on: |  |
| Disseminated to: |  |
| Equality impact assessment: |  |
| NCL Joint Formulary Committee Approval date: |  |
| Review date: |  |

Contents

[1. Target audience 4](#_Toc441155225)

[2. Purpose 4](#_Toc441155226)

[3. Abbreviations 4](#_Toc441155227)

[4. Introduction 4](#_Toc441155228)

[5. Heading 1 (example) 4](#_Toc441155229)

[5.1. Heading 2 (example) 4](#_Toc441155230)

[5.1.1. Heading 3 (example) 4](#_Toc441155231)

[6. References 4](#_Toc441155232)

[7. Associated documents 4](#_Toc441155233)

[Appendix 1: Appendix name 4](#_Toc441155234)

[Appendix 2: Example flow diagram 4](#_Toc441155235)

1. Target audience

Eg. Hospital or Primary care

1. Purpose

Describe the purpose of the document

1. Abbreviations

Explain all definitions

1. Introduction

Optional section

1. Heading 1 (example)

Example

* 1. Heading 2 (example)

Example

* + 1. Heading 3 (example)

Example

Subheading (example)

Example

1. References

Provide an up-to-date evidence base for procedural documents using Vancouver style. Websites should include hyperlinks and ‘date last accessed’, SPCs should include title in full, manufacturer and date last updated on eMC.

1. Associated documents

Optional section

Appendix 1: Summary of treatment recommendations

Insert text

Insert text

Insert text

Insert text

Insert text

Insert text

Insert text

Insert text

Insert text

Insert text

Insert text

Insert text

Appendix : Optional appendix name

Insert appendix